The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Mississauga

Monday Deal Review: May 25, 2009

bignickel1This week’s deal review has a couple of new placements, a couple of new plants, a very interesting claim asserted in Boston, and many, many updates on deals we have previously covered.  Check out the full review after the jump…

BIO 2009: Ontario Premier’s Breakfast

BIO 2009The speeches (s-peach-es?) just finished this morning at the Ontario Premier’s breakfast.

Minister of Research and Innovation John Wilkinson announced that Ontario has recently completed 2 new BIP investments:

Ontario’s Premier — Dalton McGuinty, winner of BIO’s second annual International Leadership Award — spoke next, highlighting the Ontario Innovation Agenda, including BIP, business tax reductions and recent funding in the Emerging Technologies Fund and the new $100 million for genomics research.

Dr. Nagy also spoke, emphasizing the $100 million of new funding and the value of a peer group of 95 P.I.’s in Ontario working on stem cells and regenerative medicine. Current work focuses on cell type switching without regression to pluripotency.

On to the omelet…

P.S.  First time here at the Cross-Border Biotech Blog?  Welcome! Check out who we are, check out our Trends in 2009 series, or hit the search and navigation tools on your right and see if you see anything interesting.

Bookmark and Share

Takeda Comes to Canada

Takeda expanded into Canada today with the establishment of Takeda Canada Inc., which will be headquartered in Mississauga.

Takeda’s primary therapeutic areas include diabetes, cardiovascular disease, CNS disorders, gastroenterology, bone and joint disorders, chronic kidney disease/anemia and gynecological disorders.

Takeda Canada will register and commercialize medicines from Takeda’s portfolio of primary care and specialty products. Takeda Canada intends to file its first New Drug Submission (NDS) by the end of 2009.

Welcome to Canada!

More from the press release after the jump…

Follow

Get every new post delivered to your Inbox.

Join 130 other followers